Bio-Techne Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.6%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
$2.05next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth Quarterly300.0%Target: Double-digit organic growth
Adjusted Operating Margin Quarterly3,420.0%Target: 35.0% within five years
Wilson Wolf Revenue Growth Annually2,000.0%Target: Sustained high-growth milestones for full acquisition by end of calendar 2027
Watch Items
- Biotech Funding Environment and Emerging Biotech SpendingTrigger: Mid-single-digit decline in emerging biotech customer segmentAction: Monitor industry funding data, venture capital inflows, and customer order conversion timelines to assess recovery pace.
- FDA Fast Track Customer HeadwindsTrigger: 300 basis point headwind on organic revenue growthAction: Track clinical trial progress and commercial supply order schedules for key cell therapy clients.
Research as of 2 Sep 2026